treatment with an experimental drug cabozantinib or chemotherapy for ocular melanoma

What we are studying

The purpose of this study is to test whether the new treatment with an experimental drug, known as cabozantinib is more effective than chemotherapy for treating ocular melanoma. Cabozantinib may work by blocking a protein called MET which is often found to be an important cause of the growth and spread of ocular melanoma.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18 - 90

Eligibility Criteria

  • Some previous treatment allowed; patients must be able to swallow pills

What is involved

  • Study participants will receive 28-day cycles of cabozantinib vs temozolomide or dacarbazine (21-day cycle).

Contact Information

Study Coordinator
Tom Freeman
Email
thfreema@wakehealth.edu
Phone
336-713-6914

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.